COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #113
Source   PDF   Share   Tweet
See all 181 studies
Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Ferri at al., Clinical Rheumatology, doi:0.1007/s10067-020-05334-7 (Peer Reviewed)
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
Analysis of 1641 systemic autoimmune disease patients showing csDMARD (HC Q etc.) RR 0.37, p=0.015.
csDMARDs include HC Q, C Q, and several other drugs, so the effect of HC Q/C Q alone could be higher.
This study also confirms that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, OR 4.42, p<0.001 (this is the observed real-world risk which takes into account factors such as these patients potentially being more careful to avoid exposure).
(results are for "definite + highly suspected" cases and the main result is presented in the paper as the OR for not taking csDMARDs, we have converted this to RR for taking csDMARDs).
COVID-19 case, ↓63.0%, p=0.01, risk of COVID-19 case
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.